Company Description
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.
The company was founded in 2008 and is headquartered in Jerusalem, Israel.
| Country | Israel |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Ilan Hadar |
Contact Details
Address: The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr Jerusalem, 9112001 Israel | |
| Phone | 972 2 674 3430 |
| Website | silexion.com |
Stock Details
| Ticker Symbol | SLXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2022416 |
| CUSIP Number | G1281K130 |
| ISIN Number | KYG1281K1307 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ilan Hadar M.B.A. | Chairman and Chief Executive Officer |
| Mirit Horenshtein Hadar | Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary |
| Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific and Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2026 | 10-K/A | [Amend] Annual report |
| May 18, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | 8-K | Current Report |
| May 13, 2026 | 8-K | Current Report |
| May 11, 2026 | EFFECT | Notice of Effectiveness |
| May 11, 2026 | EFFECT | Notice of Effectiveness |
| May 7, 2026 | POS AM | Post-Effective amendments for registration statement |